Atakan Demir1, Nil Molinas Mandel2, Semra Paydas3, Gökhan Demir1, Özlem Er1, Nazım Serdal Turhal4, Sevil Bavbek5, Yeşim Eralp1, Pınar Mualla Saip6, Emine Nilüfer Güler7, Adnan Aydıner6, Başak Oyan Uluç1, Sadettin Kılıçkap7, Necdet Üskent4, Nuri Karadurmuş8, Mehmet Ali Kaplan9, Mustafa Teoman Yanmaz10, Hacer Demir11, Özkan Alan12, Taner Korkmaz1, Polat Olgun13, Özlem Sönmez Uysal1, Kadri Altundağ14, Şeyda Gündüz15, Meral Günaldı16, Murat Sarı5, İsmail Beypınar11, Gül Başaran1. 1. Department of Medical Oncology, Acıbadem University, İstanbul, Turkey 2. Clinic of Oncology, American Hospital, İstanbul, Turkey 3. Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey 4. Clinic of Oncology, Anadolu Medical Center Hospital, Kocaeli, Turkey 5. Self-employed, İstanbul, Turkey 6. Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey 7. Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey 8. Clinic of Medical Oncology T.C. Ministry of Health Gülhane Training and Research Hospital, Ankara, Turkey 9. Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey 10. Şişli Memorial Hospital, İstanbul, Turkey 11. Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey 12. Tekirdağ State Hospital, Tekirdağ, Turkey 13. Near East University Hospital, Lefkoşa, TRNC 14. Self-employed, Ankara, Turkey 15. Antalya Memorial Hospital, Antalya, Turkey 16. Clinic of Medical Oncology, Florya Medical Park Hospital, İstanbul, Turkey
Abstract
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.
Entities:
Keywords:
Breast cancer; palbociclib; CDK4/6 inhibitors
Authors: Luis Manso; Cristina Hernando; María Galán; Mafalda Oliveira; Miguel A Cabrera; Raquel Bratos; César A Rodríguez; Manuel Ruiz-Borrego; Salvador Blanch; Antonio Llombart-Cussac; Juan I Delgado-Mingorance; Iñaki Álvarez-Busto; Isabel Gallegos; Lucía González-Cortijo; Serafín Morales; Elena Aguirre; Blanca A Hernando; Ana Ballesteros; José E Alés-Martínez; Cristina Reboredo; Amparo Oltra; María González-Cao; Marta Santisteban; Diego Malón; Isabel Echeverría; Elisa García-Garre; Estela Vega; Sònia Servitja; Raquel Andrés; Carlos E Robles; Rafael López; Elena Galve; María J Echarri; Marta Legeren; Fernando Moreno Journal: Breast Date: 2020-11-13 Impact factor: 4.380